A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan

von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding symptoms. Acquired von Willebrand syndrome (AVWS) is rare, but potentially underdiagnosed, and develops in various underlying disorders. AVWS caused...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Seminars in thrombosis and hemostasis Ročník 48; číslo 8; s. 911
Hlavní autoři: Ichinose, Akitada, Osaki, Tsukasa, Souri, Masayoshi, Favaloro, Emmanuel J
Médium: Journal Article
Jazyk:angličtina
Vydáno: 01.11.2022
ISSN:1098-9064, 1098-9064
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding symptoms. Acquired von Willebrand syndrome (AVWS) is rare, but potentially underdiagnosed, and develops in various underlying disorders. AVWS caused by anti-VWF autoantibodies is a rare subcategory of AVWS that can also be referred to as autoimmune VWF deficiency (AiVWFD). We performed a search of patients with autoimmune coagulation factor deficiencies in our nationwide survey in Japan. Among these, suspected cases of AiVWFD were extremely few, with only 11 case consultations in the last 10 years. Of these, three and five were respectively positive for anti-VWF autoantibodies (anti-VWF-Ab) and VWF inhibitor (VWF-inh). We also performed an extensive literature search of other cases from Japan, and in total, 40 cases were finally identified to have AiVWFD, with mean age of 55.0 years. Most underlying disorders were lympho- or myeloproliferative diseases, followed by autoimmune diseases. The major bleeding sites were subcutaneous and mucosal, the bleeding severity was moderate, and there were no hemorrhagic deaths. Bleeding time was prolonged; factor VIII activity, VWF antigen, and VWF activity were decreased, and high-molecular-weight VWF multimers were absent or decreased. These are similar to the common abnormal laboratory findings observed among general AVWS cases. Hemostatic therapy often involved VWF concentrates and vasopressin, and antibody eradication therapy often included corticosteroids and achieved remission. Notably, of all cases, 68% had anti-VWF-Abs, and 83% of anti-VWF-Ab-positive patients were also VWF-inh positive. To accumulate precise clinical information on AiVWFD, it is necessary to verify and improve the measurement methods for both anti-VWF-Ab and anti-VWF-inh. These findings from Japan should be confirmed in other geographic localities.von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding symptoms. Acquired von Willebrand syndrome (AVWS) is rare, but potentially underdiagnosed, and develops in various underlying disorders. AVWS caused by anti-VWF autoantibodies is a rare subcategory of AVWS that can also be referred to as autoimmune VWF deficiency (AiVWFD). We performed a search of patients with autoimmune coagulation factor deficiencies in our nationwide survey in Japan. Among these, suspected cases of AiVWFD were extremely few, with only 11 case consultations in the last 10 years. Of these, three and five were respectively positive for anti-VWF autoantibodies (anti-VWF-Ab) and VWF inhibitor (VWF-inh). We also performed an extensive literature search of other cases from Japan, and in total, 40 cases were finally identified to have AiVWFD, with mean age of 55.0 years. Most underlying disorders were lympho- or myeloproliferative diseases, followed by autoimmune diseases. The major bleeding sites were subcutaneous and mucosal, the bleeding severity was moderate, and there were no hemorrhagic deaths. Bleeding time was prolonged; factor VIII activity, VWF antigen, and VWF activity were decreased, and high-molecular-weight VWF multimers were absent or decreased. These are similar to the common abnormal laboratory findings observed among general AVWS cases. Hemostatic therapy often involved VWF concentrates and vasopressin, and antibody eradication therapy often included corticosteroids and achieved remission. Notably, of all cases, 68% had anti-VWF-Abs, and 83% of anti-VWF-Ab-positive patients were also VWF-inh positive. To accumulate precise clinical information on AiVWFD, it is necessary to verify and improve the measurement methods for both anti-VWF-Ab and anti-VWF-inh. These findings from Japan should be confirmed in other geographic localities.
AbstractList von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding symptoms. Acquired von Willebrand syndrome (AVWS) is rare, but potentially underdiagnosed, and develops in various underlying disorders. AVWS caused by anti-VWF autoantibodies is a rare subcategory of AVWS that can also be referred to as autoimmune VWF deficiency (AiVWFD). We performed a search of patients with autoimmune coagulation factor deficiencies in our nationwide survey in Japan. Among these, suspected cases of AiVWFD were extremely few, with only 11 case consultations in the last 10 years. Of these, three and five were respectively positive for anti-VWF autoantibodies (anti-VWF-Ab) and VWF inhibitor (VWF-inh). We also performed an extensive literature search of other cases from Japan, and in total, 40 cases were finally identified to have AiVWFD, with mean age of 55.0 years. Most underlying disorders were lympho- or myeloproliferative diseases, followed by autoimmune diseases. The major bleeding sites were subcutaneous and mucosal, the bleeding severity was moderate, and there were no hemorrhagic deaths. Bleeding time was prolonged; factor VIII activity, VWF antigen, and VWF activity were decreased, and high-molecular-weight VWF multimers were absent or decreased. These are similar to the common abnormal laboratory findings observed among general AVWS cases. Hemostatic therapy often involved VWF concentrates and vasopressin, and antibody eradication therapy often included corticosteroids and achieved remission. Notably, of all cases, 68% had anti-VWF-Abs, and 83% of anti-VWF-Ab-positive patients were also VWF-inh positive. To accumulate precise clinical information on AiVWFD, it is necessary to verify and improve the measurement methods for both anti-VWF-Ab and anti-VWF-inh. These findings from Japan should be confirmed in other geographic localities.von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding symptoms. Acquired von Willebrand syndrome (AVWS) is rare, but potentially underdiagnosed, and develops in various underlying disorders. AVWS caused by anti-VWF autoantibodies is a rare subcategory of AVWS that can also be referred to as autoimmune VWF deficiency (AiVWFD). We performed a search of patients with autoimmune coagulation factor deficiencies in our nationwide survey in Japan. Among these, suspected cases of AiVWFD were extremely few, with only 11 case consultations in the last 10 years. Of these, three and five were respectively positive for anti-VWF autoantibodies (anti-VWF-Ab) and VWF inhibitor (VWF-inh). We also performed an extensive literature search of other cases from Japan, and in total, 40 cases were finally identified to have AiVWFD, with mean age of 55.0 years. Most underlying disorders were lympho- or myeloproliferative diseases, followed by autoimmune diseases. The major bleeding sites were subcutaneous and mucosal, the bleeding severity was moderate, and there were no hemorrhagic deaths. Bleeding time was prolonged; factor VIII activity, VWF antigen, and VWF activity were decreased, and high-molecular-weight VWF multimers were absent or decreased. These are similar to the common abnormal laboratory findings observed among general AVWS cases. Hemostatic therapy often involved VWF concentrates and vasopressin, and antibody eradication therapy often included corticosteroids and achieved remission. Notably, of all cases, 68% had anti-VWF-Abs, and 83% of anti-VWF-Ab-positive patients were also VWF-inh positive. To accumulate precise clinical information on AiVWFD, it is necessary to verify and improve the measurement methods for both anti-VWF-Ab and anti-VWF-inh. These findings from Japan should be confirmed in other geographic localities.
Author Ichinose, Akitada
Favaloro, Emmanuel J
Osaki, Tsukasa
Souri, Masayoshi
Author_xml – sequence: 1
  givenname: Akitada
  surname: Ichinose
  fullname: Ichinose, Akitada
– sequence: 2
  givenname: Tsukasa
  surname: Osaki
  fullname: Osaki, Tsukasa
– sequence: 3
  givenname: Masayoshi
  surname: Souri
  fullname: Souri, Masayoshi
– sequence: 4
  givenname: Emmanuel J
  surname: Favaloro
  fullname: Favaloro, Emmanuel J
BookMark eNpNjs9LwzAYQINMcJtePefoJfolTZv0WKabk4EgiseRH18h0iZb00787xX04Om90-MtyCymiIRcc7jlUJZ3mQFIwbiSNWh9RuYcas1qqOTsn1-QRc4fAFxqEHOybegLngJ-0tTSZhpT6PspIm3ccQoDenpKkb6HrkM7mOjp2rgxDfQe2-ACRvdFQ6RP5mDiJTlvTZfx6o9L8rZ-eF09st3zZrtqdswVqhqZ1V6YUjjrhEdplai91W2r4OdQGbDS27LwCjR6XihlsLBV7bUDW5StM1wsyc1v9zCk44R53PchO-w6EzFNeS8qrZQQlSzENwDcUg0
CitedBy_id crossref_primary_10_1055_a_2002_2394
crossref_primary_10_1055_s_0044_1787188
crossref_primary_10_1055_a_2576_5019
crossref_primary_10_1055_s_0044_1782197
crossref_primary_10_3390_ijms232314715
crossref_primary_10_1055_s_0043_1766093
crossref_primary_10_1016_j_jtha_2022_11_019
crossref_primary_10_1055_s_0042_1756301
crossref_primary_10_1007_s12185_024_03782_4
ContentType Journal Article
Copyright Thieme. All rights reserved.
Copyright_xml – notice: Thieme. All rights reserved.
DBID 7X8
DOI 10.1055/s-0042-1749088
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1098-9064
GroupedDBID ---
0R~
123
4.4
53G
5RE
5~~
7X8
AAIWL
ABJNI
ABOCM
ABZLV
ACGFO
ACGFS
ACNUY
AENEX
AEVEF
AGCGI
AHRAW
AHRSK
AIVKU
AJGCD
AKJTW
ALMA_UNASSIGNED_HOLDINGS
BPGNG
C45
CS3
DU5
EXEOM
F5P
H13
IY8
J5H
N9A
O9-
OVD
P2P
Q3R
QTC
RTC
TEORI
TWZ
YFH
ID FETCH-LOGICAL-c376t-b8d2a52cbc2de4b729db8ff701097a0b4db53d708ed1377ae3b69d8c0b35fca12
IEDL.DBID 7X8
ISICitedReferencesCount 11
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000822068500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-9064
IngestDate Fri Jul 11 11:24:36 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c376t-b8d2a52cbc2de4b729db8ff701097a0b4db53d708ed1377ae3b69d8c0b35fca12
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
PQID 2687722643
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2687722643
PublicationCentury 2000
PublicationDate 2022-11-01
PublicationDateYYYYMMDD 2022-11-01
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-01
  day: 01
PublicationDecade 2020
PublicationTitle Seminars in thrombosis and hemostasis
PublicationYear 2022
SSID ssj0014802
Score 2.4197211
SecondaryResourceType review_article
Snippet von Willebrand factor (VWF) forms high-molecular-weight multimers and plays an essential role in hemostasis, and thus its deficiency leads to bleeding...
SourceID proquest
SourceType Aggregation Database
StartPage 911
Title A Review of Autoimmune Acquired von Willebrand Factor Deficiency in Japan
URI https://www.proquest.com/docview/2687722643
Volume 48
WOSCitedRecordID wos000822068500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4Ft9E8BpMs5tN9iSLWlSweFDoreQJvWTVbfv7zaQpPXgRvOcQksnMl_nmm0HopoJrVlYQb-r4QeFaEt3nnkTHWFW-YI5qmoZNiOFQjkb1W064dbmscukTk6O2rYEc-S2rZASCMXwXd59fBKZGAbuaR2iso14RoQxYtRitWIRS5prDOj7qGHuXTRs5v-1IEqZEPA6FPr8ccYoug93_7msP7WRciZuFIeyjNRcO0NZrZs4P0XODFzQAbj1uZtN2AsIQhxsDpcDO4nkbMCRfgEgOFg_SHB784KDDBMgz8STglxhZwxH6GDy-3z-RPEaBmOg9pkRLyxRnRhtmXakjmrZaei-AFBOK6tJqXlhBpbPQflC5Qle1lYbqgnuj-uwYbYQ2uBOEbcR7UklVi5qWXvQ1taXRkkulvfGOn6Lr5SGNo5kC96CCa2fdeHVMZ39Yc462GcgMkubvAvV8fIruEm2a-XTSfV-lW_4BK3KxDA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Review+of+Autoimmune+Acquired+von+Willebrand+Factor+Deficiency+in+Japan&rft.jtitle=Seminars+in+thrombosis+and+hemostasis&rft.au=Ichinose%2C+Akitada&rft.au=Osaki%2C+Tsukasa&rft.au=Souri%2C+Masayoshi&rft.au=Favaloro%2C+Emmanuel+J&rft.date=2022-11-01&rft.issn=1098-9064&rft.eissn=1098-9064&rft.volume=48&rft.issue=8&rft.spage=911&rft_id=info:doi/10.1055%2Fs-0042-1749088&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-9064&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-9064&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-9064&client=summon